Clinical trial No longer in our active list Phase 3 Interventional Ages 18 to 130

Investigating Dato-DXd with or without Osimertinib for advanced lung cancer

Official title: A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

Run by AstraZeneca · NCT06417814 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new treatment called Dato-DXd, with and without another drug called osimertinib, to see if it helps people with advanced lung cancer who have already tried other therapies.

More Metastatic Non Small Cell Lung Cancer trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 130 Years
SexAll
Enrollment744 (estimated)
SponsorAstraZeneca
Industry-sponsored
Drugs / interventionsosimertinib, chemotherapy, immunotherapy, radiation
Locations302 sites (Fayetteville, Arkansas and 301 other locations)
Trial IDNCT06417814 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with histologically confirmed non-squamous NSCLC who have documented EGFR mutations and have experienced disease progression on prior osimertinib treatment.

Probably not a fit

Patients with squamous cell carcinoma or those who have not received prior osimertinib may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase III, open-label, multicenter study evaluates the efficacy and safety of Dato-DXd, both in combination with osimertinib and as a monotherapy, compared to standard platinum-based doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will be randomized into three groups to assess progression-free survival (PFS) and safety outcomes. The study aims to provide insights into treatment options for patients whose disease has progressed after prior osimertinib therapy.

Why it matters

Potential benefit: If successful, this study could offer a new effective treatment option for patients with advanced EGFR-mutated NSCLC.

How similar studies have gone: Other studies have shown promising results with similar targeted therapies in EGFR-mutated lung cancer, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically or cytologically confirmed non-squamous NSCLC.
* Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKis\] sensitivity \[Ex19del, L858R, G719X, S768I, or L861Q\], either alone or in combination with other EGFR mutations, which may include T790M).
* Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent line of treatment) in the adjuvant, locally advanced, or metastatic setting.
* Less than or equal to (\<=2) prior lines of EGFR TKIs (osimertinib is the only permitted prior third generation EGFR TKI).
* At least one lesion, not previously irradiated, that qualifies as a RECIST v1.1 TL at baseline and can be accurately measured at baseline.
* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate bone marrow reserve and organ function within 7 days before randomization.

Exclusion Criteria:

* Use of chemotherapy, vascular endothelial growth factor inhibitor, immunotherapy or any anti-cancer therapy in the metastatic setting. Platinum-based chemotherapy in non-metastatic setting within 12 months prior to randomization.
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before the first dose of study intervention.
* Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.
* Has significant third-space fluid retention (example \[eg.\], ascites or pleural effusion) as judged by the investigator and is not amenable for required repeated drainage.
* History of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids or drug-induced ILD, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
* Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses.
* Unstable spinal cord compression and/or unstable brain metastases.
* Participants with symptomatic brain metastases (including leptomeningeal involvement).
* Clinically significant corneal disease.
* Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections. Use of systemic antibiotics within 14 days of randomization.
* Has known human immunodeficiency virus (HIV) infection that is not well controlled.

Where it's running

  • Research Site
    Fayetteville, Arkansas, United States
    Recruiting
  • Research Site
    Fountain Valley, California, United States
    Recruiting
  • Research Site
    La Jolla, California, United States
    Recruiting
  • Research Site
    Colorado Springs, Colorado, United States
    Recruiting
  • Research Site
    Fort Collins, Colorado, United States
    Recruiting
  • Research Site
    Jacksonville, Florida, United States
    Recruiting
Show 44 more locations
  • Research Site
    Athens, Georgia, United States
    Recruiting
  • Research Site
    Evanston, Illinois, United States
    Recruiting
  • Research Site
    Louisville, Kentucky, United States
    Recruiting
  • Research Site
    Baltimore, Maryland, United States
    Recruiting
  • Research Site
    Bethesda, Maryland, United States
    Recruiting
  • Research Site
    Boston, Massachusetts, United States
    Recruiting
  • Research Site
    Detroit, Michigan, United States
    Recruiting
  • Research Site
    Kansas City, Missouri, United States
    Recruiting
  • Research Site
    Omaha, Nebraska, United States
    Recruiting
  • Research Site
    Morristown, New Jersey, United States
    Recruiting
  • Research Site
    Northfield, New Jersey, United States
    Recruiting
  • Research Site
    New York, New York, United States
    Recruiting
  • Research Site
    The Bronx, New York, United States
    Recruiting
  • Research Site
    Maumee, Ohio, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania, United States
    Recruiting
  • Research Site
    Chattanooga, Tennessee, United States
    Recruiting
  • Research Site
    Nashville, Tennessee, United States
    Recruiting
  • Research Site
    Fairfax, Virginia, United States
    Recruiting
  • Research Site
    Fitzroy, Australia
    Recruiting
  • Research Site
    Heidelberg, Australia
    Recruiting
  • Research Site
    Kogarah, Australia
    Recruiting
  • Research Site
    Liverpool, Australia
    Recruiting
  • Research Site
    Nedlands, Australia
    Recruiting
  • Research Site
    Port Macquarie, Australia
    Recruiting
  • Research Site
    St Leonards, Australia
    Recruiting
  • Research Site
    Westmead, Australia
    Recruiting
  • Research Site
    Woolloongabba, Australia
    Recruiting
  • Research Site
    Charleroi, Belgium
    Recruiting
  • Research Site
    Edegem, Belgium
    Recruiting
  • Research Site
    Ghent, Belgium
    Recruiting
  • Research Site
    Hasselt, Belgium
    Recruiting
  • Research Site
    Jette, Belgium
    Recruiting
  • Research Site
    La Louvière, Belgium
    Recruiting
  • Research Site
    Leuven, Belgium
    Recruiting
  • Research Site
    Namur, Belgium
    Recruiting
  • Research Site
    Roeselare, Belgium
    Recruiting
  • Research Site
    Itajaí, Brazil
    Recruiting
  • Research Site
    Brampton, Ontario, Canada
    Recruiting
  • Research Site
    Toronto, Ontario, Canada
    Recruiting
  • Research Site
    Toronto, Ontario, Canada
    Recruiting
  • Research Site
    Montreal, Quebec, Canada
    Recruiting
  • Research Site
    Baoding, China
    Recruiting
  • Research Site
    Beijing, China
    Recruiting
  • Research Site
    Beijing, China
    Recruiting

+252 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.